speb/financial-data huggingface dataset:
AMBUJACEM.NS income_statement (annual, 2021-12-31) — Total Other Finance Cost: 70000000.00
AMBUJACEM.NS balance_sheet (annual, 2021-12-31) — Total Tax Payable: 19059000000.00
AMBUJACEM.NS balance_sheet (annual, 2021-12-31) — Work In Process: 7847300000.00
AMBUJACEM.NS balance_sheet (annual, 2021-12-31) — Working Capital: 57932200000.00
AMBUJACEM.NS income_statement (annual, 2021-12-31) — Write Off: -108700000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — +Operating Expense: 246855600000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — +Total Revenue: 309828300000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Basic Average Shares: 1986127049.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Basic EPS: 9.76
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Beginning Cash Position: 113584900000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Capital Expenditure: -45540400000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Cash Dividends Paid: -12512600000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Change In Inventory: -6083600000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Change In Payable: -2551300000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Change In Receivables: -27296200000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Change In Working Capital: -35931100000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Changes In Cash: -48898600000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Common Stock Issuance: 50000300000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Cost Of Revenue: 37076300000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Depreciation: 12923400000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Depreciation And Amortization: 12923400000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Depreciation And Amortization In Income Statement: 12923400000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Depreciation Income Statement: 12923400000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Diluted Average Shares: 2027677824.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Diluted EPS: 9.56
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Diluted NI Availto Com Stockholders: 19384600000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Dividends Received Cfi: 68900000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — EBIT: 28960700000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — EBITDA: 41884100000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — End Cash Position: 64744100000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Financing Cash Flow: 30517500000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Free Cash Flow: -53902400000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Gain Loss On Investment Securities: -341500000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of Business: -165200000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Gain Loss On Sale Of PPE: -16100000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Gross Profit: 272752000000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Interest Expense: 1554700000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Interest Expense Non Operating: 1554700000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Interest Paid Cff: -880200000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Interest Received Cfi: 3512400000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Investing Cash Flow: -71054100000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Issuance Of Capital Stock: 50000300000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Long Term Debt Payments: -35900000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Minority Interests: -3226200000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Net Common Stock Issuance: 50000300000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Net Income: 19384600000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Net Income Common Stockholders: 19384600000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Net Income Continuous Operations: 22610800000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Net Income From Continuing And Discontinued Operation: 19384600000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Net Income From Continuing Operation Net Minority Interest: 19384600000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Net Income From Continuing Operations: 27406000000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Net Income Including Noncontrolling Interests: 22610800000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Net Interest Income: -1554700000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Net Investment Purchase And Sale: -30199300000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Net Issuance Payments Of Debt: -35900000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Net Long Term Debt Issuance: -35900000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Net Non Operating Interest Income Expense: -1554700000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Net Other Financing Charges: 4100000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Net Other Investing Changes: 628400000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Net PPE Purchase And Sale: -45064500000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Normalized EBITDA: 43603200000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Normalized Income: 20802910818.07
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Operating Cash Flow: -8362000000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Operating Income: 25896400000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Operating Revenue: 309828300000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Other Cash Adjustment Outside Changein Cash: 57800000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Other Non Cash Items: -2692400000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Other Non Operating Income Expenses: 4546000000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Other Operating Expenses: 143625900000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Other Special Charges: 1719100000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Otherunder Preferred Stock Dividend: 0.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Pretax Income: 27406000000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Purchase Of PPE: -45540400000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Reconciled Cost Of Revenue: 37076300000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Reconciled Depreciation: 12923400000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Repayment Of Debt: -35900000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Sale Of PPE: 475900000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Selling And Marketing Expense: 75613700000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Selling General And Administration: 75613700000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Special Income Charges: -1719100000.00
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Stock Based Compensation: 29400000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Tax Effect Of Unusual Items: -300789181.93
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Tax Provision: 4795200000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Tax Rate For Calcs: 0.17
AMBUJACEM.NS cash_flow (annual, 2022-12-31) — Taxes Refund Paid: -9376900000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Total Expenses: 283931900000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Total Unusual Items: -1719100000.00
AMBUJACEM.NS income_statement (annual, 2022-12-31) — Total Unusual Items Excluding Goodwill: -1719100000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — +Operating Expense: 202383300000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — +Total Revenue: 325297900000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Accounts Payable: 29640700000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Accounts Receivable: 11895900000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Accumulated Depreciation: -98410900000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Additional Paid In Capital: 213200200000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Allowance For Doubtful Accounts Receivable: -851000000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Amortization: 627300000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Amortization Cash Flow: 627300000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Assets Held For Sale Current: 219300000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Available For Sale Securities: 455300000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Basic Average Shares: 1987962505.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Basic EPS: 17.98
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Beginning Cash Position: 5438700000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Buildings And Improvements: 46768400000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Capital Expenditure: -44824600000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Capital Lease Obligations: 6622300000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Capital Stock: 4395400000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Cash And Cash Equivalents: 30071000000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Cash Cash Equivalents And Short Term Investments: 149307600000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Cash Dividends Paid: -4964100000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Cash Equivalents: 23669200000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Cash Financial: 6401800000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Change In Inventory: -2282900000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Change In Other Current Assets: 9752400000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Change In Other Current Liabilities: -7260200000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Change In Payable: 1029800000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Change In Receivables: 243500000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Change In Working Capital: 1940900000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Changes In Cash: 23841600000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Common Stock: 4395400000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Common Stock Equity: 414516800000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Common Stock Issuance: 66609600000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Construction In Progress: 26584500000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Cost Of Revenue: 75108600000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Current Assets: 239662300000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Current Capital Lease Obligation: 1631800000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Current Debt: 178700000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Current Debt And Capital Lease Obligation: 1810500000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Current Liabilities: 121288800000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Current Provisions: 429700000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Depreciation: 15651700000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Depreciation And Amortization: 16279000000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Depreciation And Amortization In Income Statement: 16279000000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Depreciation Income Statement: 15651700000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Diluted Average Shares: 2145703372.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Diluted EPS: 16.65
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Diluted NI Availto Com Stockholders: 35734000000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Dividends Payable: 468800000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Dividends Received Cfi: 260400000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — EBIT: 61724800000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — EBITDA: 78003800000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — End Cash Position: 30071000000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 239000000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Financing Cash Flow: 56887700000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Finished Goods: 2918000000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Free Cash Flow: 11633600000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Gain Loss On Investment Securities: -576100000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of Business: 0.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Gain Loss On Sale Of PPE: -1158100000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — General And Administrative Expense: 1618200000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Goodwill: 88027500000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Goodwill And Other Intangible Assets: 114493900000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Gross Accounts Receivable: 12746900000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Gross PPE: 332444900000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Gross Profit: 250189300000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Impairment Of Capital Assets: 0.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Interest Expense: 2763800000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Interest Expense Non Operating: 2763800000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Interest Income: 9369000000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Interest Income Non Operating: 9369000000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Interest Paid Cff: -2340800000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Interest Received Cfi: 10036000000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Inventory: 36085500000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Invested Capital: 414884600000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Investing Cash Flow: -89504300000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Investmentin Financial Assets: 694300000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Issuance Of Capital Stock: 66609600000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Issuance Of Debt: 0.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Land And Improvements: 27812500000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Long Term Capital Lease Obligation: 4990500000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Long Term Debt: 189100000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Long Term Debt And Capital Lease Obligation: 5179600000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Long Term Debt Issuance: 0.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Long Term Debt Payments: -240500000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Long Term Equity Investment: 622600000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Long Term Provisions: 2559700000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Machinery Furniture Equipment: 226247800000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Minority Interest: 93908400000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Minority Interests: -11612300000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Net Business Purchase And Sale: -23082200000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Net Common Stock Issuance: 66609600000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Net Foreign Currency Exchange Gain Loss: 24700000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Net Income: 35734000000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Net Income Common Stockholders: 35734000000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Net Income Continuous Operations: 47346300000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Net Income From Continuing And Discontinued Operation: 35734000000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Net Income From Continuing Operation Net Minority Interest: 35734000000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Net Income From Continuing Operations: 58961000000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Net Income Including Noncontrolling Interests: 47346300000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Net Interest Income: 6605200000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Net Investment Purchase And Sale: -16251000000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Net Issuance Payments Of Debt: -240500000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Net Long Term Debt Issuance: -240500000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Net Non Operating Interest Income Expense: 6605200000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Net PPE: 234034000000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Net PPE Purchase And Sale: -39611400000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Net Tangible Assets: 300022900000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Revenue: 0.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Assets: 369400000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Non Current Deferred Taxes Liabilities: 13583500000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Non Current Prepaid Assets: 31604300000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Normalized EBITDA: 74100500000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Normalized Income: 32602772740.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Operating Cash Flow: 56458200000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Operating Income: 47806000000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Operating Revenue: 325297900000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Ordinary Shares Number: 2197675987.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Other Cash Adjustment Outside Changein Cash: 790700000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Other Current Assets: 703400000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Other Current Liabilities: 9608200000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Other Equity Interest: 27923500000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Other Intangible Assets: 26466400000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Other Inventories: 15677100000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Other Non Cash Items: -8656000000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Other Non Current Assets: 28426000000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Other Non Operating Income Expenses: 507400000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Other Operating Expenses: 92561400000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Other Payable: 34311000000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Other Properties: 5031700000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Other Receivables: 12283500000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Other Short Term Investments: 119236600000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Other Special Charges: -1019700000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Otherunder Preferred Stock Dividend: 0.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Payables: 90969900000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Pensionand Other Post Retirement Benefit Plans Current: 429700000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Prepaid Assets: 27122400000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Pretax Income: 58961000000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Properties: 0.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Provisionand Write Offof Assets: -1160600000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Purchase Of Business: -23542700000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Purchase Of Investment: -16785700000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Purchase Of PPE: -44824600000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Raw Materials: 9502600000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Reconciled Cost Of Revenue: 75108600000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Reconciled Depreciation: 16279000000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Rent And Landing Fees: 1180000000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Rent Expense Supplemental: 1180000000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Repayment Of Debt: -240500000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Restricted Cash: 2264000000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Restructuring And Mergern Acquisition: -2252900000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Retained Earnings: 109143300000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Sale Of Business: 460500000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Sale Of Investment: 534700000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Sale Of PPE: 5213200000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Selling And Marketing Expense: 82777900000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Selling General And Administration: 84396100000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Share Issued: 2197675987.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Special Income Charges: 3272600000.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Stock Based Compensation: 0.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Stockholders Equity: 414516800000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Tangible Book Value: 300022900000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Tax Effect Of Unusual Items: 772072740.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Tax Provision: 11614700000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Tax Rate For Calcs: 0.20
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Taxes Receivable: 0.00
AMBUJACEM.NS cash_flow (annual, 2024-03-31) — Taxes Refund Paid: -9155600000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Total Assets: 651036800000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Total Capitalization: 414705900000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Total Debt: 6990100000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Total Equity Gross Minority Interest: 508425200000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Total Expenses: 277491900000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Total Liabilities Net Minority Interest: 142611600000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Total Non Current Assets: 411374500000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Total Non Current Liabilities Net Minority Interest: 21322800000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Total Tax Payable: 26549400000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Total Unusual Items: 3903300000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Total Unusual Items Excluding Goodwill: 3903300000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Work In Process: 7987800000.00
AMBUJACEM.NS balance_sheet (annual, 2024-03-31) — Working Capital: 118373500000.00
AMBUJACEM.NS income_statement (annual, 2024-03-31) — Write Off: 0.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Accounts Payable: 34514500000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Accounts Receivable: 18894900000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Available For Sale Securities: 15435300000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Capital Lease Obligations: 7387200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Capital Stock: 4926200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Cash And Cash Equivalents: 22690500000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Cash Cash Equivalents And Short Term Investments: 116977200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Common Stock: 4926200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Common Stock Equity: 503756500000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Construction In Progress: 64716100000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Current Assets: 225676500000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Current Capital Lease Obligation: 1851000000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Current Debt: 112100000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Current Debt And Capital Lease Obligation: 1963100000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Current Liabilities: 133099100000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Current Provisions: 428700000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Goodwill: 108560700000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Goodwill And Other Intangible Assets: 167568800000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Gross PPE: 305722000000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Inventory: 41716600000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Invested Capital: 504161700000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Investmentin Financial Assets: 15435300000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Capital Lease Obligation: 5536200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt: 293100000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Debt And Capital Lease Obligation: 5829300000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Equity Investment: 570700000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Long Term Provisions: 2940900000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Minority Interest: 95402800000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Net PPE: 305722000000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Net Tangible Assets: 336187700000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Assets: 1773500000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Non Current Deferred Taxes Liabilities: 23904700000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Ordinary Shares Number: 2463123478.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Other Current Assets: 48007900000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Other Current Liabilities: 34455100000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Other Equity Interest: 498830300000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Other Intangible Assets: 59008100000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Other Non Current Assets: 36034100000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Other Properties: 241005900000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Other Receivables: 79900000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Other Short Term Investments: 94286700000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Payables: 63432800000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Share Issued: 2463123478.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Stockholders Equity: 503756500000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Tangible Book Value: 336187700000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Total Assets: 765719700000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Total Capitalization: 504049600000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Total Debt: 7792400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Total Equity Gross Minority Interest: 599159300000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Total Liabilities Net Minority Interest: 166560400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Assets: 540043200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Total Non Current Liabilities Net Minority Interest: 33461300000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Total Tax Payable: 28918300000.00
AMBUJACEM.NS balance_sheet (quarterly, 2024-09-30) — Working Capital: 92577400000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — +Operating Expense: 55875000000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — +Total Revenue: 84981000000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Basic Average Shares: 2435902935.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Basic EPS: 8.86
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Cost Of Revenue: 18054300000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Depreciation And Amortization In Income Statement: 6066800000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Depreciation Income Statement: 6066800000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 2435902935.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Diluted EPS: 8.86
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Diluted NI Availto Com Stockholders: 21582100000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — EBIT: 24603600000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — EBITDA: 30670400000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Gross Profit: 66926700000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Impairment Of Capital Assets: 0.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Interest Expense: 669900000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Interest Expense Non Operating: 669900000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Minority Interests: -5047600000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Net Income: 21582100000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Net Income Common Stockholders: 21582100000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Net Income Continuous Operations: 26629700000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing And Discontinued Operation: 21582100000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: 21582100000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Net Income Including Noncontrolling Interests: 26629700000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Net Interest Income: -669900000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Net Non Operating Interest Income Expense: -669900000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Normalized EBITDA: 30670400000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Normalized Income: 21582100000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Operating Income: 11051700000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Operating Revenue: 84981000000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Other Non Operating Income Expenses: 13522400000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Other Operating Expenses: 34679900000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Otherunder Preferred Stock Dividend: 0.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Pretax Income: 23933700000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Reconciled Cost Of Revenue: 18054300000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Reconciled Depreciation: 6066800000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Selling And Marketing Expense: 20437500000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Selling General And Administration: 20437500000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Special Income Charges: 0.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Tax Effect Of Unusual Items: 0.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Tax Provision: -2696000000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Tax Rate For Calcs: 0.30
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Total Expenses: 73929300000.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items: 0.00
AMBUJACEM.NS income_statement (quarterly, 2024-12-31) — Total Unusual Items Excluding Goodwill: 0.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — +Operating Expense: 215945700000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — +Operating Expense: 68939800000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — +Total Revenue: 336540700000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — +Total Revenue: 98944100000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Accounts Payable: 29948400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 29948400000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Accounts Receivable: 15903000000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 15903000000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Accumulated Depreciation: -120314200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Accumulated Depreciation: -120314200000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Additional Paid In Capital: 323856800000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 323856800000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -1070200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -1070200000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Amortization: 2566700000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Amortization Cash Flow: 2566700000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Available For Sale Securities: 650600000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Available For Sale Securities: 650600000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Basic Average Shares: 2451487424.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Basic Average Shares: 2465120192.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Basic EPS: 17.55
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Basic EPS: 4.16
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Beginning Cash Position: 47426100000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Buildings And Improvements: 57528000000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Buildings And Improvements: 57528000000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Capital Expenditure: -86870500000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Capital Lease Obligations: 7616800000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 7616800000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Capital Stock: 4926200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Capital Stock: 4926200000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Cash And Cash Equivalents: 50433200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 50433200000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 79732900000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 79732900000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Cash Dividends Paid: -4926300000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Cash Equivalents: 41407400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Cash Equivalents: 41407400000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Cash Financial: 9025800000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Cash Financial: 9025800000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Change In Inventory: -5128900000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Change In Other Current Assets: -13001500000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Change In Other Current Liabilities: -5595300000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Change In Payable: -5762900000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Change In Receivables: -3823200000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Change In Working Capital: -34012200000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Changes In Cash: 2982900000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Common Stock: 4926200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Common Stock: 4926200000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Common Stock Equity: 535789200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 535789200000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Common Stock Issuance: 83390900000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Construction In Progress: 113177400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Construction In Progress: 113177400000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Cost Of Revenue: 83792600000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 18268300000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Current Assets: 194358800000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Current Assets: 194358800000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Current Capital Lease Obligation: 3041400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 3041400000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Current Debt: 124300000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Current Debt: 124300000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Current Debt And Capital Lease Obligation: 3165700000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 3165700000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Current Liabilities: 138452600000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 138452600000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Current Provisions: 550900000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Current Provisions: 550900000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Depreciation: 20403700000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Depreciation And Amortization: 22970400000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Depreciation And Amortization In Income Statement: 22970400000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Depreciation And Amortization In Income Statement: 6938500000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Depreciation Income Statement: 20403700000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Depreciation Income Statement: 6938500000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Diluted Average Shares: 2457585687.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 2465120192.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Diluted EPS: 17.51
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Diluted EPS: 4.16
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Diluted NI Availto Com Stockholders: 43031000000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 10254900000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Dividends Payable: 438800000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Dividends Payable: 438800000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Dividends Received Cfi: 150700000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — EBIT: 63196100000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — EBIT: 18863500000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — EBITDA: 86166500000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — EBITDA: 25802000000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — End Cash Position: 50433200000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 266600000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Financial Assets Designatedas Fair Value Through Profitor Loss Total: 266600000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Financing Cash Flow: 55920400000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Finished Goods: 4324400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Finished Goods: 4324400000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Free Cash Flow: -64497000000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Gain Loss On Investment Securities: -1434400000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Gain Loss On Sale Of PPE: -357900000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — General And Administrative Expense: 2925900000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Goodwill: 109428300000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Goodwill: 109428300000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Goodwill And Other Intangible Assets: 119808800000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 119808800000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Gross Accounts Receivable: 16973200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 16973200000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Gross PPE: 541997000000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Gross PPE: 541997000000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Gross Profit: 252748100000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Gross Profit: 80675800000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Hedging Assets Current: 0.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Hedging Assets Current: 0.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Held To Maturity Securities: 0.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Held To Maturity Securities: 0.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Impairment Of Capital Assets: 2072800000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Impairment Of Capital Assets: 2072800000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Interest Expense: 2159400000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Interest Expense: 142900000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Interest Expense Non Operating: 2159400000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 142900000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Interest Income: 24339100000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Interest Income Non Operating: 24339100000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Interest Paid Cff: -1757900000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Interest Received Cfi: 9815600000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Inventory: 42480100000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Inventory: 42480100000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Invested Capital: 536057400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Invested Capital: 536057400000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Investing Cash Flow: -75311000000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Investmentin Financial Assets: 917200000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Investmentin Financial Assets: 917200000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Issuance Of Capital Stock: 83390900000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Issuance Of Debt: 97200000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Land And Improvements: 42988100000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Land And Improvements: 42988100000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Long Term Capital Lease Obligation: 4575400000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 4575400000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Long Term Debt: 143900000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 143900000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 4719300000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 4719300000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Long Term Debt Issuance: 97200000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Long Term Debt Payments: -11808300000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Long Term Equity Investment: 603900000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Equity Investment: 603900000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Long Term Provisions: 2540800000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Long Term Provisions: 2540800000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Machinery Furniture Equipment: 22999700000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Machinery Furniture Equipment: 22999700000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Minority Interest: 103681700000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Minority Interest: 103681700000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Minority Interests: -9909800000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Minority Interests: -3259700000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Net Business Purchase And Sale: -42487400000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Net Common Stock Issuance: 83390900000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Net Foreign Currency Exchange Gain Loss: 61600000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Net Income: 43031000000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Net Income: 10254900000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Net Income Common Stockholders: 43031000000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 10254900000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Net Income Continuous Operations: 52940800000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 13514600000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 43031000000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 10254900000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 43031000000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 10254900000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Net Income From Continuing Operations: 61036700000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Net Income Including Noncontrolling Interests: 52940800000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 13514600000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Net Interest Income: 22179700000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Net Interest Income: -142900000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Net Investment Purchase And Sale: 43073300000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Net Issuance Payments Of Debt: -11711100000.00
AMBUJACEM.NS cash_flow (annual, 2025-03-31) — Net Long Term Debt Issuance: -11711100000.00
AMBUJACEM.NS income_statement (annual, 2025-03-31) — Net Non Operating Interest Income Expense: 22179700000.00
AMBUJACEM.NS income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: -142900000.00
AMBUJACEM.NS balance_sheet (annual, 2025-03-31) — Net PPE: 421682800000.00
AMBUJACEM.NS balance_sheet (quarterly, 2025-03-31) — Net PPE: 421682800000.00